Italia markets closed

ALEC May 2024 7.500 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,0000-0,5000 (-20,00%)
Alla chiusura: 03:01PM EDT
Schermo intero
Chiusura precedente2,5000
Aperto2,0000
Denaro1,7000
Lettera4,7000
Prezzo d'esercizio7,50
Scadenza2024-05-17
Min-Max giorno2,0000 - 2,0000
Contratto - Min-MaxN/D
Volume1
Open Interest1
  • GlobeNewswire

    Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease

    Data readout expected in Q4 2024SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Data from the trial are expected in the fourth quarter of 2024. AL00

  • GlobeNewswire

    Alector to Participate in Upcoming Healthcare Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference (New York, New York) Monday, September 11, 2023 at 4:55 p.m. ET, fireside chat H.C. Wainwright 25th Annual Global Investment Conference (New York, New York) Tuesday, September 12, 2023 a

  • GlobeNewswire

    Alector Reports Second Quarter 2023 Financial Results and Provides Business Update

    Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer’s disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 Presented update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC) Anticipate completing enrollment in pivotal INFRONT-3 trial of latozinemab with symptomatic FTD-GRN participants in Q4 2023 based on recent interactions with the FDA and EMA $630.0 million in cash, cash equivalents and investments p